About Amicus Therapeutics
Amicus Therapeutics is a publicly listed company based in Philadelphia (United States) founded in 2002, and was acquired by BioMarin Pharmaceutical in December 2025. Developer of therapies for rare and orphan diseases. Amicus Therapeutics has raised $91 million across 13 funding rounds from investors including BioMarin Pharmaceutical, Blackstone and Frazier Healthcare Partners. The company has 499 employees. Amicus Therapeutics has completed 2 acquisitions, including Callidus Biopharma and Scioderm. Its chief executive, as recorded, is Bradley L Campbell. Its website amicusrx.com draws about 20 thousand monthly visits. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Amicus Therapeutics was founded in 2002 and is headquartered in Philadelphia, United States. Operations center on the biotechnology sector, where small-molecule therapies for rare and orphan diseases are advanced. A pipeline of pharmacological chaperones targets lysosomal storage disorders such as Fabry, Pompe, and Gaucher diseases. Key candidates include migalastat, an oral treatment for Fabry disease, and SD-101 for the genetic disorder Epidermolysis Bullosa.
- Headquarters Philadelphia, United States
- Employees 499
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website amicusrx.com
- Social LinkedIn X YouTube
- Acquired by BioMarin Pharmaceutical (Dec 2025)
- Legal Name Amicus Therapeutics, Inc.
- Annual Revenue$528.29 M (USD)32.29as on Dec 31, 2024
- Net Profit-$56.11 M (USD)62.99as on Dec 31, 2024
- EBITDA$42.61 M (USD)164.93as on Dec 31, 2024
- Total Equity Funding$91M (USD)
in 13 rounds
- Latest Funding Round$30M (USD), Post-IPO
Oct 2023
- InvestorsBioMarin Pharmaceutical
& 10 more
- Employee Count499
- Investments & AcquisitionsCallidus Biopharma
& 1 more
- Acquired byBioMarin Pharmaceutical
(Dec 2025)
Apps and channels of Amicus Therapeutics
its YouTube channel Amicus Therapeutics has 107 subscribers and 6 videos.
Videos from Amicus Therapeutics
The most watched videos on Amicus Therapeutics's YouTube channel, Amicus Therapeutics (107 subscribers). Click a video to play it here.
More on Amicus Therapeutics.
Funding Insights of Amicus Therapeutics
Amicus Therapeutics has successfully raised a total of $91M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $91M
- Total Rounds 13
- Last Round Post-IPO — $30M
- First Round $2M
(Jul 2002)
- Investors Count 10
Latest 10 of 13 funding rounds of Amicus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $30M | Post-IPO | – | – | |
| Feb 2018 | $300M | Post-IPO | – | – | – |
| Apr 2017 | $21.79M | Post-IPO | – | – | |
| Dec 2016 | $250M | Post-IPO | – | – | – |
| Dec 2013 | $15M | Post-IPO | – | – | – |
| Jul 2012 | $18.58M | Post-IPO | – | – | – |
| Dec 2010 | $500,000 | Grant | – | – | |
| Sep 2005 | $55M | Series C | – | Quaker Partners Management | |
| May 2004 | $31M | Series B | – | – | |
| Dec 2003 | $1M | Seed | – | – | – |
11 investors in total: 11 institutional.
Investors in Amicus Therapeutics
Amicus Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, Blackstone and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Early stage healthcare services investments are facilitated by CHL. | chlmedical.com | Westport, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
| radiusventures.com | ||||
| quakerpartners.com | ||||
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for Amicus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amicus Therapeutics
163 people are tracked at Amicus Therapeutics (105 in leadership, 9 in board & advisors, 49 in team); the tracked headcount is 499.
| Name | Role | Group |
|---|---|---|
Bradley L Campbell | CEO & President | Leadership |
Ellen S. Rosenberg | Chief Legal Officer | Leadership |
Jeffrey P. Castelli | Chief Portfolio Officer and Head of Gene Therapy | Leadership |
Jayne C. Gershkowitz | Chief Patient Advocate Emerita | Leadership |
Patrik Florencio | Senior Vice President, Global Chief Compliance & Risk Officer | Leadership |
Jill Weimer | Chief Science Officer | Leadership |
Sheela Sitaraman Das | Head Of Program Management | Leadership |
Chi Tarn | Executive Director, Program Alignment Team Lead | Leadership |
Sarah Russell | Director, Regulatory Affairs | Leadership |
Barri Boylan | Senior Director, Legal Counsel | Leadership |
Irina Demo | Director, Enterprise Applications | Leadership |
Ryan Graham | Executive Director | Leadership |
Sam Shiu | Head Of Information Security | Leadership |
Eoin Duff | Director: Quality Compliance And Operational Excellence | Leadership |
Claire Crowley | Senior Vice President, HR | Leadership |
David Clark | Chief People Officer | Leadership |
Vipul Jain | Director | Leadership |
Yang Xu | Senior Director, Legal, Intellectual Property | Leadership |
Andy Madson | Regional Business Director-west | Leadership |
Assad Meyer | Director & Country Manager Switzerland | Leadership |
143 more people are available in the full profile.
Complete people profiles for Amicus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Amicus Therapeutics
Amicus Therapeutics is a publicly listed company on the NASDAQ with ticker symbol FOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 May 2007
- Listed onNASDAQ: FOLD
- Listed entityAmicus Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS03152W1099
- Share price$14.49 (+0.21% on the day) · 2026-04-28
- Market capitalisation$4.55B
- EPS (diluted, trailing year)$-0.09
- Volume (last session)5,285,334
- Analyst consensusNeutral
Financials of Amicus Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $528.3M | -$56.1M | $42.6M |
| 2023 | $399.4M | -$151.6M | -$65.6M |
| 2022 | $329.2M | -$236.6M | -$199.1M |
| 2021 | $305.5M | -$250.5M | -$193.7M |
| 2020 | $260.9M | -$276.9M | -$235.0M |
Detailed financial statements for Amicus Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amicus Therapeutics
Amicus Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Callidus Biopharma and Scioderm.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Topical therapies are developed for chronic skin diseases treatment. | sderm.com | Durham, United States | 2012 | Aug 2015 | $229M | |
Enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs) | callidusbiopharma.com | Doylestown, United States | 2010 | Nov 2013 | •••• |
Complete acquisition details for Amicus Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Amicus Therapeutics
7 dated milestones of Amicus Therapeutics across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Amicus Therapeutics is founded.
- Funding First funding round of $2.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Callidus Biopharma.
- Acquisition Acquires Scioderm.
- Funding Latest funding round, Post-IPO, of $30.0M.
- Exit Acquired by BioMarin Pharmaceutical.
Competitors of Amicus Therapeutics
Amicus Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Amicus Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Amicus Therapeutics
The website of Amicus Therapeutics (amicusrx.com) receives about 20.4K visits a month and ranks #1,355,769 among all websites worldwide, #1,758 in Biotechnology and Pharmaceuticals.
- Monthly visits20.4K
▲ 4.9% vs previous month
- Unique visitors9K
per month
- Global rank#1,355,769
among all websites
- Category rank#1,758
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.9
- Average visit46 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Amicus Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nektar.com | 100% | 19.6K | #959,308 | View details | |
| neurenpharma.com | 100% | 9.6K | #2,553,786 | View details | |
| g1therapeutics.com | 89% | 2.8K | #6,603,375 | View details | |
| abeonatherapeutics.com | 89% | 8K | #2,941,685 | View details | |
| ptcbio.com | 88% | 24.4K | #1,154,739 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for Amicus Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Amicus Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amicus Therapeutics
Complete news archive for Amicus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amicus Therapeutics
Amicus Therapeutics was founded in 2002.
Amicus Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Bradley L Campbell is the CEO of Amicus Therapeutics, as recorded in our data.
Amicus Therapeutics is a funded company, having raised a total of $91M across 13 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jul 2002.
Amicus Therapeutics has 499 employees.
Annual revenue of Amicus Therapeutics is $528.29M as on Dec 31, 2024.
Amicus Therapeutics was founded in 2002 and is headquartered in Philadelphia, United States. Operations center on the biotechnology sector, where small-molecule therapies for rare and orphan diseases are advanced. A pipeline of pharmacological chaperones targets lysosomal storage disorders such as Fabry, Pompe, and Gaucher diseases. Key candidates include migalastat, an oral treatment for Fabry disease, and SD-101 for the genetic disorder Epidermolysis Bullosa.
Amicus Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Amicus Therapeutics is publicly traded on NASDAQ under the ticker symbol FOLD.
Amicus Therapeutics has made 2 acquisitions, including Callidus Biopharma, and Scioderm.
Amicus Therapeutics has 11 investors. Key investors include BioMarin Pharmaceutical, Blackstone, Frazier Healthcare Partners, Canaan, and The Michael J. Fox Foundation.
Yes. Amicus Therapeutics was acquired by BioMarin Pharmaceutical in December 2025.